NeurogesX Initiates Dosing In Phase 1 Clinical Trial For NGX-1998 Capsaicin Liquid Formulation NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced the initiation of its Phase 1 clinical trial (study C203) of NGX-1998. The product candidate is a high-concentration, capsaicin-based liquid formulation designed to deliver a localized therapeutic dose directly to the pain site.
Source: www.medicalnewstoday.com
# posted by Network @ 2:01 AM
